Zexing Sun
Hematology researcher in Hangzhou who studies treatment of bone-marrow failure, including the use of sirolimus (rapamycin) in pure red cell aplasia
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine) and The First School of Clinical Medicine, Zhejiang Chinese Medical University (papers 2026)
In pure red cell aplasia, the bone marrow stops making red blood cells while white cells and platelets are spared. The acquired form is often driven by the immune system, so it is treated with immune-suppressing drugs such as ciclosporin. In SUN2026, Zexing Sun and colleagues in Dijiong Wu's group looked back at patients treated at one hospital whose disease had not responded to ciclosporin and who then received sirolimus, the drug also called rapamycin, which blocks mTOR in immune cells. 54.5 percent responded, and 64.3 percent of those whose aplasia was secondary to another disease. Responses did not depend on mutations in STAT3 or STAT5B, genes often altered in the abnormal lymphocytes linked to this disease. The study was retrospective, at one centre, with no randomised control group, so it cannot prove that sirolimus works better than ciclosporin.
Sun works in the Department of Hematology of the First Affiliated Hospital of Zhejiang Chinese Medical University in Hangzhou. In 2026 the same group also published a single-centre comparison of stem cell transplant donor types in aplastic anaemia, on which Sun was a co-author. No personal institutional page was found, so the affiliation shown is the one on the Atlas paper.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Favorable response to second-line sirolimus regardless of STAT3/5b status in acquired pure red cell aplasia: A retrospective study from a single center. SUN2026 First author of the retrospective single-centre study in which second-line sirolimus produced responses in ciclosporin-refractory acquired pure red cell aplasia regardless of STAT3/STAT5B status. |
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.